There was no consensus as to whether individuals with a GPV in an intermediate penetrance CSG (ATM, CHEK2, RAD51C, RAD51D, BARD1 or BRIP1) should be proactively recontacted regarding breast cancer surveillance at any stage, assuming that appropriate advice and onward referrals had been made after their results appointment. The gene discussed is CHEK2; the disease is breast carcinoma.